Affiliation:
1. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
2. People’s Hospital of Longhua, The affiliated hospital of Southern Medical University, Shenzhen 518109, China
Abstract
Tumor-associated macrophages (TAMs) are one of the most plentiful immune compositions in the tumor microenvironment, which are further divided into anti-tumor M1 subtype and pro-tumor M2 subtype. Recent findings found that TAMs play a vital function in the regulation and progression of tumorigenesis. Moreover, TAMs promote tumor vascularization, and support the survival of tumor cells, causing an impact on tumor growth and patient prognosis. Numerous studies show that reducing the density of TAMs, or modulating the polarization of TAMs, can inhibit tumor growth, indicating that TAMs are a promising target for tumor immunotherapy. Recently, clinical trials have found that treatments targeting TAMs have achieved encouraging results, and the U.S. Food and Drug Administration has approved a number of drugs for use in cancer treatment. In this review, we summarize the origin, polarization, and function of TAMs, and emphasize the therapeutic strategies targeting TAMs in cancer treatment in clinical studies and scientific research, which demonstrate a broad prospect of TAMs-targeted therapies in tumor immunotherapy.
Funder
National Natural Science Foundation of China
Shenzhen Longhua District Science and Technology Innovation Fund
Open Project of Scientific Research Workstation of the Chinese Disease Control Journal
Reference194 articles.
1. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth;Joyce;Cancer Cell,2023
2. Alternative Activation of Macrophages: Mechanism and Functions;Gordon;Immunity,2010
3. Boutilier, A.J., and Elsawa, S.F. (2021). Macrophage Polarization States in the Tumor Microenvironment. Int. J. Mol. Sci., 22.
4. Protective and pathogenic functions of macrophage subsets;Murray;Nat. Rev. Immunol.,2011
5. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors;Lee;Investig. New Drugs,2020